Loading, Please Wait...
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and mast cell related diseases, today announced financial results for the second quarter ended June 30, 2018.
Second Quarter 2018 Financial Results
Research and development expenses were $7.1 million in the second quarter of 2018 as compared to $3.8 million in the same period in 2017. The increase in research and development expenses was primarily related to an increase in consulting and personnel-related costs, as well as contract research and development activities related to the continued advancement of AK002, the Company’s lead antibody.
General and administrative expenses were $2.4 million in the second quarter of 2018 as compared to $0.8 million in the same period in 2017. The increase in general and administrative expenses was primarily attributable to an increase in personnel-related costs as a result of the Company’s increase in employee headcount, as well as incremental expense incurred from outside professional service providers for legal, information technology, and investor relations support in preparation for the Company’s initial public offering.
Allakos reported a net loss of $9.4 million in the second quarter of 2018 as compared to $4.7 million in the same period in 2017, an increase of $4.7 million. Net loss per basic and diluted share was $4.17 for the second quarter of 2018 compared to $3.18 in the same period in 2017. Net loss per basic and diluted share is based on a weighted-average number of shares outstanding in the period, and therefore, does not include shares sold in the Company’s initial public offering and concurrent private placement on July 23, 2018.
Allakos ended the second quarter of 2018 with $64.1 million in cash, cash equivalents and marketable securities, which does not include $141.8 million of proceeds, net of underwriting discounts and commissions, received from the Company’s initial public offering and concurrent private placement on July 23, 2018.
Allakos is a clinical stage company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed two Phase 1 trials, one in healthy volunteers and a single ascending dose trial in patients with indolent systemic mastocytosis. AK002 demonstrated pharmacodynamic activity in both trials and in the trial involving patients with indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a phase 2 trial for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis. In addition, Allakos is conducting multiple dose trials with AK002 in chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. For more information, please visit the Company's website at www.allakos.com.
Source: Allakos Inc.
|CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS|
|(in thousands, except per share data)|
Three Months Ended
Six Months Ended
|Research and development||$||7,149||$||3,758||$||13,550||$||8,122|
|General and administrative||2,375||840||4,683||1,453|
|Total operating expenses||9,524||4,598||18,233||9,575|
|Loss from operations||(9,524||)||(4,598||)||(18,233||)||(9,575||)|
|Interest income (expense), net||292||(73||)||516||(137||)|
|Other expense, net||(145||)||(21||)||(145||)||(36||)|
|Unrealized gain on marketable securities, net of tax||3||—||3||—|
|Net loss per common share:|
|Basic and diluted||$||(4.17||)||$||(3.18||)||$||(8.36||)||$||(6.73||)|
|Weighted-average number of common shares outstanding:|
|Basic and diluted||2,248||1,477||2,137||1,449|
|CONDENSED balance sheets|
|(in thousands, except per share data)|
|June 30,||December 31,|
|Cash and cash equivalents||$||19,295||$||85,207|
|Investments in marketable securities||44,851||—|
|Prepaid expenses and other current assets||2,987||1,037|
|Total current assets||67,133||86,244|
|Property and equipment, net||3,376||445|
|Other long-term assets||3,716||340|
|Liabilities, Convertible Preferred Stock and Stockholders' Deficit|
|Accrued expenses and other current liabilities||3,082||1,089|
|Total current liabilities||5,010||2,792|
|Other long-term liabilities||1,468||36|
|Convertible preferred stock||143,019||142,969|
|Additional paid-in capital||3,158||1,803|
|Accumulated other comprehensive income||3||—|
|Total stockholders’ deficit||(75,272||)||(58,768||)|
|Total liabilities, convertible preferred stock, and stockholders’ deficit||$||74,225||$||87,029|
Investor Contact: Adam Tomasi, COO, CFO firstname.lastname@example.org Media Contact: Denise Powell email@example.com